All posts by medical

Too Much Information? FDA Clears 23AndMe to Sell Home Genetic Tests for Alzheimer’s and Parkinson’s – Scientific American

Genetic testing company 23AndMe is back with a controversial new offering, after the U.S. Food and Drug Administration on Thursday green-lighted the companys request to market a fresh batch of direct-to-consumer tests. Soon, with a simple saliva swab dropped in the mail, customers will be able to get answers about their genetic risk for developing 10 maladiesincluding Parkinsons disease and late-onset Alzheimers.

The FDA approval will likely reignite a long-simmering debate about when and how such tests should be used. Even when there are strong links between certain gene variants and medical conditions, genetic information often remains difficult to interpret. It must be balanced against other factors including health status, lifestyle and environmental influences, which could sharpen or weaken risk. If disease risk news is delivered at homewithout a genetic counselor or doctor on hand to offer contextmany geneticists fear it can lead to unnecessary stress, confusion and misunderstandings.

Against that backdrop, the FDAs decision came with caveats: Results obtained from the tests should not be used for diagnosis or to inform treatment decisions, the agency said in a statement. It added that false positive and false negative findings are possible.

But geneticist Michael Watson, executive director of the American College of Medical Genetics and Genomics, thinks consumers will have trouble making such distinctions and says he doubts people will view them as a mere novelty. Watson also worries 23AndMes wares may create other problems: Follow-up testing for some of these conditions may be quite pricey, he says, and insurance companies might not cover that cost if a person has no symptoms. He also notes that some of the conditions involved may have no proved treatments, leaving consumers with major concernsand few options to address them, aside from steps like making some lifestyle changes.

The makeup of 23AndMes reports to consumers is still being finalized, but the company says it does not expect to grade or rank a persons risk of developing any of the 10 conditions approved for analysis. Instead it will simply report a person has a gene variant associated with any of the maladies and is at an increased risk, the company told Scientific American.

The FDA decision may significantly widen the companys market and top off a years-long debate about what sort of genetic information should be available to consumers without professional medical oversight. After the FDAs 2013 decision to stop 23AndMe from sharing data about disease risk with its customers, the company was still able to offer them information about their genetic ancestry. It has also been selling consumer tests for genes that would indicate whether people are carriers for more than 30 heritable conditions, including cystic fibrosis and Tay-Sachs disease.

This month 23AndMe plans to release its first set of genetic health-risk reports for late-onset Alzheimers disease, Parkinsons disease, hereditary thrombophilia (a blood-clotting disorder), alpha 1-antitrypsin deficiency (a condition that raises the risk of lung and liver disease), and a new carrier status report for Gauchers disease (an organ and tissue disorder). Reports for other tests will follow, the company says.

In considering whether to approve the tests, the FDA says it reviewed studies that demonstrated the 23AndMe procedures correctly and consistently identified variants associated with the 10 conditions. Further data from peer-reviewed scientific literature demonstrated the links between these gene variants and conditions, and supported the underlying science.

The FDA also announced on Thursday that it plans to offer the company exemptions for similar genetic tests in the future, without requiring them to be submitted for premarket review. That decision could leave the door open to offering tests for other conditions that have questionable reproducibility, says Jim Evans, a genetics and medicine professor at the University of North Carolina School of Medicine.

Read the original post:
Too Much Information? FDA Clears 23AndMe to Sell Home Genetic Tests for Alzheimer's and Parkinson's - Scientific American

Cancer Genetics, Inc. is Selected by eFFECTOR Therapeutics to Provide Biomarker Discovery and Development … – GlobeNewswire (press release)

April 10, 2017 07:00 ET | Source: Cancer Genetics, Inc.

RUTHERFORD, N.J. and SAN DIEGO, April 10, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (CGI or The Company), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that it has been chosen by eFFECTOR Therapeutics, Inc., a biopharmaceutical company developing selective translation regulators for the treatment of cancer, to provide clinical biomarker services for eFFECTORs lead product candidate eFT508. The two companies will work together on eFFECTORs strategies to implement studies aiding in biomarker discovery and development, including immuno-oncology biomarkers, allowing further optimization of eFT508 development as a single agent and in drug combinations.

eFT508 is a novel, potent and highly selective oral small molecule inhibitor of MNK1 and 2 (MAP kinase-interacting kinase 1 and 2). MNK1 and MNK2 integrate signals from several oncogenic and immune signaling pathways, including RAS, Toll-like receptors and the T-cell receptor, by phosphorylating eukaryotic initiation factor 4E (eIF4E) and other key effector proteins. Phosphorylation of these RNA-binding proteins by MNK1 and MNK2 selectively regulates the stability and translation of a subset of cellular mRNA that control cell signaling within and between tumor and immune cells, the tumor microenvironment and immune cell function. In preclinical studies, eFT508 has demonstrated activity in multiple tumor models as well as establishment of anti-tumor immune memory.

eFT508 is currently in Phase 1/2 clinical development targeting multiple solid tumors and lymphoma, and has been recently granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of diffuse large B-cell lymphoma (DLBCL). eFFECTOR has designed a biomarker strategy to demonstrate target engagement, inform patient selection and validate the immunological mechanism of action of the drug. These biomarkers will allow for the determination of both circulating and tumor infiltrating immune cell types and their activation state in patients before and after treatment with eFT508 across the ongoing clinical program.

Our collaboration with CGI will allow us to measure several important biomarkers that may reflect eFT508s mechanism of action, as well as identify responsive patient populations, said Kevin Webster, Ph.D., Senior Vice President of eFFECTOR Therapeutics. This will be particularly useful for eFT508, which acts both on tumor cell intrinsic signaling and on extrinsic signaling within tumor infiltrating immune cells, leading to induction of anti-tumor immunity in addition to direct anti-tumor activity.

Cancer Genetics is currently supporting over 125 clinical trials and studies globally with 40 focused on immune therapies. Panna Sharma, CEO and President of CGI commented, The ability to partner with innovative therapeutic companies and help with the critical work across critical topics such as biomarker discovery, identification of immune markers, and immunological mechanisms of action of the drug is a testament to the value and depth of our capabilities and portfolio. Our expanding customer base of highly innovative companies, such as eFFECTOR, highlights our value proposition to the biopharma community. We are very motivated by this opportunity and ready to empower eFFECTOR to achieve important clinical milestones through the use of CGIs extensive oncology-focused menu and biomarker development expertise.

About eFFECTOR Therapeutics eFFECTOR Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of selective translation regulators as a new class of small molecule therapeutics for cancer. The companys investigational compounds are designed to restore translational control to halt underlying disease mechanisms while preserving healthy physiological processes. eFFECTORs most advanced program focuses on the development of eFT508. The company has additional selective translation regulator programs currently in discovery and development. For more information visit http://www.effector.com.

About Cancer Genetics, Inc. Cancer Genetics, Inc. is an emerging leader in enabling precision medicine for oncology through the use of molecular markers and information. CGI is developing a global footprint with locations in the US, India and China. It has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.

The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.

For more information, please visit or follow us:

Internet:www.cancergenetics.com Twitter:@Cancer_Genetics Facebook:www.facebook.com/CancerGenetics

Forward-Looking Statements: This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in revenues, margins, research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. tests and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements.

Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the discovery, development and/or commercialization of potential therapies or products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Form 10-K for the year ended December 31, 2016 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.

Related Articles

Rutherford, New Jersey, UNITED STATES

http://cancergenetics.com

Cancer Genetics, Inc. Logo

LOGO URL | Copy the link below

Formats available:

See the rest here:
Cancer Genetics, Inc. is Selected by eFFECTOR Therapeutics to Provide Biomarker Discovery and Development ... - GlobeNewswire (press release)

BRIEF-Beijing Leadman Biochemistry Co Ltd sees Q1 FY 2017 net profit down 10 pct to up 10 pct – Reuters

April 10 Beijing Leadman Biochemistry Co Ltd

* Sees Q1 FY 2017 net profit to decrease by 10 percent to increase by 10 percent, or to be 16.2 million yuan to 19.8 million yuan

* Says Q1 FY 2016 net profit was 18 million yuan

* The reason for the forecast is strengthened the management of customer credit account, reduced bad debts risk and decreased income

Source text in Chinese:goo.gl/9R9L4c

Further company coverage: (Beijing Headline News)

April 10 Denmark will on Wednesday lift an order to keep poultry flocks indoors as the threat of bird flu has lessened, the Ministry of Environment and Food said in a press release on Monday.

* Organigram enters into LoI to acquire Trauma Healing Centers

See original here:
BRIEF-Beijing Leadman Biochemistry Co Ltd sees Q1 FY 2017 net profit down 10 pct to up 10 pct - Reuters

$75 million neuroscience center opens on Phalen Boulevard, St … – TwinCities.com-Pioneer Press

To design the five-level, $75 million HealthPartners Neuroscience Center opening Monday at 295 Phalen Boulevard, directors traveled as far as the Spaulding Rehabilitation Center in Cambridge, Mass., for ideas on how tokeep the atmosphere patient-friendly and aggressively state-of-the-art.

A recent tour of the facility illustrates that approach.

Inside the 130,000-square-foot facility, video cameras linked to two underwater treadmills record and analyze the gait of stroke victims in a climate-controlled therapy pool. A floor below, 16 privately-funded researchers surrounded by beakers, microscopesand hypersensitive digital scales search for cures to dementia and Alzheimers disease.

A floor above, images displayed on large flat-screen wall monitors will show patients the interior of their own tumors, spines and frontal lobes, a visual road map to complicatedmedical conditions. Clinical trials, physical rehab, patient diagnosis and lab work will all happen in the same building.

It was a really long journey making sure every aspect of the building was patient-centric, said Marny Farrell, the centers director of rehabilitation for outpatient services.

The result is anoutpatient clinical, rehab and research space dedicated to virtually any kind of neurological condition, from stroke trauma to spinal injuries, and dementiato amyotrophic lateral sclerosis (ALS).

More than 50,000 patients a year are expected to use the new center, which will employ some 200 physicians and staffers.

More importantly, the centercombines neuroscience specialties under one roof, allowing them room to expand. And it frees up needed space at Regions and at HealthPartners two nearby clinical centers, at 401 and 435 Phalen Boulevard, where research and medical services also are growing.

As a result, rather than travel between three or more locations for care, dementia patients will be able to schedule an X-ray or MRI and meet with nutritionists, speech pathologists and other experts on the same day and in the same facility.

Before, it was very hard for patients to know where to go, said Dr. Bret Haake, chief medical officer with Regions Hospital, who oversaw much of the centers planning. In many academic centers, sometimes theres a lot of distance between what the lab is doing and applying it to patients.

Patients will range from hospital referrals to walk-ins, and services are being scheduled around specific types of neurological conditions.

The centers second and third floors are devoted to clinical care such as pain management, neuro-psychology and clinical research.

Large sliding doors on patient care rooms have been designed with wheelchairs in mind. Services have been segregated by noise and intensity, so a Gingko Coffeehouse and gym-like rehab center on the ground level are well removed from a meditation room and quiet areas where families might await a loved ones diagnosis.

From the rehab center, glass bay windows provide a ready line-of-sight to Regions Hospital and downtown St. Paul, as well an outdoor space fashioned with wide stone steps a practice walking area designed with stroke patients in mind.

Indoors, an overhead harness system linked to a programmable robot is capable of carrying up to 95 percent of the weight of a 450-pound patient, or as little as 5 percent. Sliding levels of support are designed to help patients regaining their ambulatory skills after a stroke or injury.

In a lower-level laboratory, groups of researchers are juggling some 40 projects related to neurological disorders, about half of them dedicated to Alzheimers. Among them, theyll publish between 10 and 20 academic papers annually. Their research tends to draw more private grants and donations than government funding, allowing greater flexibility.

Our work tends to be more cutting edge, based on prevention of brain and spine disease high risk, high reward, said Leah Hanson, senior director of neuroscience research.

Phalen Boulevard has had the early makings of a modern medical corridor; in 2005, HealthPartners built the first of two specialty centers with clinics that range in focus from ears, nose and throat to hands and plastics. The specialty center at 405 Phalen Boulevard opened that year, and 435 Phalen Boulevard opened in 2007.

The new Neuroscience Centerreplaced a smaller HealthPartners physical therapy clinic, as well as a private storage facility, and could help boost the health care companys visibility.

The structure was designed by BWBR Architects and built by Kraus-Anderson Construction.

Residents will be able to examine the finished product from the inside during a community open house from 11 a.m. to 2 p.m. on May 13.

More here:
$75 million neuroscience center opens on Phalen Boulevard, St ... - TwinCities.com-Pioneer Press

How to Keep Mistakes From Snowballing, According to Neuroscience – Inc.com

To err is human, as the saying goes. And in many ways, when we learn from what goes wrong, we become better people. But, as Laurel Hamers of Science News reports, neuroscience now shows that, when you screw up, there's a right way and a wrong way to respond.

To take a hard look at how the brain reacts to mistakes, a team of researchers led by psychologist George Buzzell had 23 individuals look at concentric circles flashed briefly on a screen. In each challenge, the colors of the circles were either the same or slightly different. The participants' had to identify the sameness or difference by raising one hand or the other.

Buzzell and his team found that the individuals participating in the study typically answered the challenge following a mistake correctly if given a second or two to recoup. But they performed worse when they weren't allowed as much recovery time after a mistake, with accuracy dropping approximately 10 percent when time between an error and a new color challenge fell to 0.2 seconds. Buzzell also looked at electrical activity from the visual cortex, the part of your brain that receives and processes information from your eyes. That data showed that making a mistake negatively affected how much the participants paid attention to the next color challenge.

Buzzell's results prove that, as the brain processes a mistake, it's temporarily distracted, making it harder for you to pay attention and move on without additional errors. It explains from a scientific perspective the dreaded snowball effect of screwups, where once you've made a mistake, if you don't have any recovery time, you keep making more blunders.

Most people become at least a little self-conscious after making a mistake. We become afraid that others will judge us as being incompetent--or just generally not good enough--because of the error. And that's terrifying, because if we're not good enough, there's very little (we believe) to stop others from kicking us to the curb and forgetting us. We don't want to be alone. On some level, we don't believe we'll survive if we are. And to pour salt in the wound, the spotlight effect, which causes people to think others are noticing things about them that they probably aren't, only magnifies our fear. We have to cope with all of this on top of what's happening in the visual cortex.

The above research should make it clear that you're not doing yourself any favors if you try to rush and immediately plow through to the next thing when a mistake happens. To get back on track and reduce the odds you keep messing up:

Remember, different situations are going to require different recovery options. It's easier to doodle at your desk, for instance, than it is onstage. But the key is to find something, any positive diversion, that gives your brain the second it needs to process and reset when you goof. Experiment to find your personal go-tos, and watch how much pressure you put on yourself. You're only human, and believe it or not, people are surprisingly approving of taking the time to do things right. You don't need to rush it, and nobody expects you to be perfect. They just expect you to try.

Read the rest here:
How to Keep Mistakes From Snowballing, According to Neuroscience - Inc.com

Cork University Hospital crisis due to lack of biochemists – Irish Examiner

A shortage of consultant clinical biochemists is causing recruitment difficulties for Cork University Hospital, where the biochemistry laboratory has advised GPs it cannot provide clinical advice or interpretation of test results because of lack of clinical governance.

Dr John O'Mullane: Retired last September.

The hospitals biochemistry department has also advised GPs it has sought to voluntarily suspend its accreditation as efforts continue to recruit a consultant clinical biochemist following the retirement, last September, of department chief Dr John OMullane.

Asked how many staff vacancies were in the department, the hospital said: At any given time, allowing that there are a great number of personnel employed in the laboratory, there can be several or no vacancies.

In terms of the current situation, the hospital said there was one consultant clinical biochemist vacancy and that its medical manpower department is actively recruiting both a locum replacement and a permanent replacement.

The hospital said as available candidates are not plentiful, it is difficult to put a timeframe on either competition.

GPs have been advised that, since March 31, the department has not been in a position to provide a clinical advisory service.

Asked what reassurance it could provide in the absence of this advisory, the hospital said the same scientists will process patient specimens to a high-quality standard, as before, and within the same timeframe.

While we can advise service users to seek appropriate advice from other sources, we cannot directly provide that advice at this time. Specific clinical advice of this nature is not generally required for the majority of results, CUH said.

Asked what loss of accreditation would mean for the hospital, the response was that CUH biochemistry will continue to maintain the existing Quality Management System...designed to ensure the safe processing of laboratory tests, but will not be able to provide clinical advice for the interpretation of results.

The hospital said accreditation an independent verification of the extent to which an organisation meets pre-determined standards is not mandatory for biochemistry laboratories but that most, including CUH, achieve it as confirmation of maintaining the system.

The biochemistry department processed approximately 8m tests last year, including for liver function, cardiac function, , and general chemistries.

Irish Examiner Ltd. All rights reserved

See more here:
Cork University Hospital crisis due to lack of biochemists - Irish Examiner

Anatomy of a Play: The Day Bryce Petty Almost Died – The Phinsider

On the 1st play of the 4th quarter in the Week 15 match-up between the Miami Dolphins and New York Jets, Bryce Petty fell victim to a snap count miscommunication and it nearly cost him his life. After Cameron Wake and Ndamukong Suhs impact, I fully expected to see Pettys intestines randomly scattered across the NFL logo on the field.

Winning 34-10, MetLife Stadium had already been taken over by a sea of aqua and orange. This play made me cringe and I was sitting in the nosebleeds. A collective ooh, with accompanying facial twitch, overcame the crowd to empathize with the pain - it must have felt like getting hit by Mike Tyson in Mike Tysons Punch-Out and a Chuck Norris roundhouse kick at the same time.

Ryan Fitzpatrick came out and put up a whopping 17.1 QB rating for the rest of the game and the rest was history. Dolphins win.

But wow, this play was almost as bad as Mark Sanchez using his face to wipe Brandon Moores butt.

Lawyer: Mr. SUTTON, what did you witness Saturday night at MetLife Stadium?

Me: I witnessed Mr. Suh and Mr. Wake kill Mr. Petty. I also saw the Jets sucking and the Dolphins not sucking.

Lawyer: And by what means did they use to (air quote) kill Mr. Petty?

Me: I thought it was a fun formation that created a little confusion: Suh and Wake at DE, Jason Jones (DE) at DT, Andre Branch (DE) at DT standing up, LBs pressing the A gaps. On this play, the Jets offense communicated about as well as Chewbacca enunciates - and it was in between quarters when the Jets conceivably had more time to not have that kind of dumb s*** happen, but, you know, its the Jets, that type of stuff happens all the time. #76, #83, and #67 literally touched nothing but air on the play. The only reason #71 touches someone is because Jason Jones runs right into him.

Lawyer: (snickers fairly loudly, coughs/clears throat, realizes he has to remain composed during the proceedings and not reveal his Dolphins loyalty) How would you describe the cause of death, sir?

Me: It was a collision sandwich. He was smushed to death. Of all the people to not only not block, but have a free sprint at your QB, you let it be Suh and Wake simultaneously?

Lawyer: Thank you, nothing further your Tannehill, I mean, your highness.

More:
Anatomy of a Play: The Day Bryce Petty Almost Died - The Phinsider

REVIEW | ‘A GAMBLER’S ANATOMY’ – The Gazette: Eastern Iowa Breaking News and Headlines

By By Rob Cline, correspondent

Apr 8, 2017 at 12:37 pm | Print View

Jonathan Lethems newest novel, A Gamblers Anatomy, is filled with masks both literal and metaphorical. Alexander Bruno, a professional backgammon play who makes his living defeating rich dilettantes, hits a catastrophic losing streak at the same time a blot begins to obscure his vision. The book follows Brunos seemingly ever more humiliating adventures, which lead to his face and his life being wholly remade.

Throughout the book, masks play an important role as characters including Bruno disguise themselves voluntarily or under duress. Lethem highlights the ways in which we are unknowable to each other and to ourselves, even when we try to strip all of our masks away.

Lethem, whose enthusiasm for the works of sci-fi author Philip K. Dick is well known, offers the reader the kind of mystery one might find in one of Dicks novels. Bruno may or may not be psychic. The blot and the growth responsible for it may or may not be dampening his abilities.

A Gamblers Anatomy also is infused with the kind of paranoia (which may not be paranoia at all) that might be found in a Thomas Pynchon novel. Bruno struggles to suss out the forces in play in his life and whether they part are part of a larger scheme.

Lethem is particularly effective in scenes featuring just two characters. He deftly uses dialogue to both illuminate and obscure his characters motivations as they jostle for position in relation to one another.

The books ending, which cannot be revealed here, is of the sort that will delight, puzzle, or disappoint some readers. I would argue that Lethem earns his unusual ending, but a case could be made that he does not and therefore leaves the reader unsatisfied at books end.

If that leaves you wondering whether you should read the book, Ill say this: I think its worth the gamble.

We make it easy to stay connected:

Read the original here:
REVIEW | 'A GAMBLER'S ANATOMY' - The Gazette: Eastern Iowa Breaking News and Headlines

Tech establishes Neuroscience major – Technique

The best things in life often take time. Thats why Georgia Techs newest major has been in the works for years. The much-anticipated Bachelors of Science in Neuroscience is the latest addition to Georgia Techs offerings.

It is easy to forget how much behind-the-scenes hard work goes into putting something like this together and making it a beneficial and smooth addition to the campus. Many faculty including Dr. Tim Cope have tirelessly worked to create a program that is the most beneficial as possible for students that might be interested in neuroscience.

Dr. Cope is a faculty member in the School of Biological Sciences, a neuroscientist, and the new director of the Neuroscience Undergraduate Curriculum Committee. In collaboration with faculty members and administration from across the schools on campus as well as universities all over the state, Dr. Cope and his colleagues have created a program that is not only meticulously crafted, but promises to offer a student experience that no other school in the state can offer.

Georgia Tech has a long tradition in quantitative science and applied science, so neuroscience here will be more technologically oriented, Cope said. Thats the tradition and the expectation on the part of the students and faculty.

Students in neuroscience will take required classes that will bestow upon them knowledge in three main focus areas: cellular and molecular biology, systems and behavior and cognitive science. After they get the basics down, students from a wide diversity of interests and backgrounds will largely be free to explore what interests them the most about neuroscience.

In an effort to facilitate this exploration, the neuroscience major will include ten Breadth Elective Specializations, which were designed by experts in the field. These specializations are biochemistry, biology, chemistry, computer science, engineering, mathematics, psychology, physics, physiology and pre-med.

Cope says that this is one of the virtues of neuroscience; it is by nature multidisciplinary and multidimensional, and can be investigated by a variety of avenues. Techs program intends to utilize many of these dimensions in a unique way.

In order to understand how brain and nervous systems work, we have to understand psych, cell biology, optics, physics, computer science and mathematics, Cope said. Our students will have all of those things. Look at what a rich intellectual environment that is. We have to bring all the info together, assimilate it and use it to figure out whats going on.

It seems that neuroscience is a rapidly evolving field, and will fit right in with other advancing topics at Tech. The faculty involved are confident that graduates will have no shortage of opportunities when its time to look for a job.

There is no human activity that I can think of that doesnt absolutely include some reliance on neuroscience, said Cope. There are so many exciting technical breakthroughs right now. There is an evidence based expectation that we are beginning to see some really important discoveries.

Neuroscience at Tech has already attracted a respectable amount of attention, with close to 100 students expressing interest in the program.

Cope says that one of their biggest challenges at this time is the unpredictability of how many students will be interested, but he and his colleagues are definitely optimistic.

One student who jumped at the chance to be one of Techs first neuroscience students was Maria Krakovski, first-year BIOL.

They tailored it super well, so I didnt waste any credits, Krakovski says. I was really happy to switch to it because its basically directed toward my interests more.

Krakovskis breadth elective specialization is pre-med, and she says she is pumped to be able to take classes that help her learn about the processes and systems of the body and how the body and brain communicate.

The major is now accepting current Tech students who wish to change their major, and will soon welcome incoming freshmen.

The enthusiasm is really very strong, Cope said. We are interested in being very creative in our delivery of the courses. We are trying to develop active learning and hands on experiences.

The various faculty members, students and supporters of the neuroscience major are anxious for the upcoming semesters and are excited to see their hard work pay off.

Here is the original post:
Tech establishes Neuroscience major - Technique

Health system, neurologists partner to form Conway Regional Neuroscience Center – Log Cabin Democrat

Neurologists Tim Freyaldenhoven and Keith Schluterman have combined their practices into a partnership with Conway Regional Health System to form the Conway Regional Neuroscience Center.

Previously the two physicians operated Arkansas Neurology in Conway.

The Conway Regional Neuroscience Center opened Feb. 20 and is located in suite 305 on the third floor of the Conway Regional Medical Plaza at the same location as the physicians clinics. Current patients should expect few changes.

Our patients will continue to have the same physicians and same excellent staff in place, Dr. Freyaldenhoven said. A major change for us is that we will get to focus more time on clinical care and less on business operations. This partnership secures neurology coverage for Conway Regional and will enable them to recruit additional neurologists to help us accommodate the needs of Faulkner County.

This will also lessen our anxiety regarding insurance coverage and fee schedule changes as well as inflation of practice costs, Dr. Schluterman said. We believe this partnership will improve continuity of care. Medical records will become more integrated and a patients clinical care can be directly carried over to hospital admissions.

Conway Regional President and CEO Matt Troup said, We will manage the business side of the practice so Dr. Freyaldenhoven and Dr. Schluterman can focus on patient care both in the center and in the hospital.

Troup added, The creation of the Conway Regional Neuroscience Center is part of our ongoing efforts to partner with our physicians. The center provides a vehicle for us to expand neurological and sleep services to the community. By aligning with Dr. Freyaldenhoven and Dr. Schluterman, we can grow their practice. It is significant that all the neurologists in Conway are aligned with Conway Regional. This will enable us to recruit to a specialty that is experiencing a national shortage. A study published in the Neurologist, the Journal of the American Academy of Neurology, indicated that the national shortage of neurologists is expected to grow to a 19 percent shortfall by 2025.

We are excited for this partnership with Drs. Schluterman and Freyaldenhoven. Its becoming more common for hospitals outside of major metropolitan areas to struggle with a consistent neurology presence, said Rebekah Fincher, Corporate Director of Physician Relations and Business Development. This partnership ensures neurology care for the community and provides Conway Regional the ability to grow and expand the neuroscience service line.

Drs. Freyaldenhoven and Schluterman have shared the same office space since 2004 and have been friends since medical school.

Both of them received their medical degrees from the University of Arkansas for Medical Sciences at Little Rock.

They have provided neurological care to Faulkner and surrounding counties since 2002, when Dr. Freyaldenhoven joined the Conway Regional Medical Staff. Dr. Schluterman followed in 2004. They are both graduates of Hendrix College.

Both physicians are board certified in general neurology and sleep medicine, and the next step will be partnering with Conway Regional to open a sleep disorders center at Conway Regional Medical Center.

Neurologists are physicians who treat illnesses of the brain and neurological system, including multiple sclerosis, epilepsy, migraine headaches, Parkinsons disease, Alzheimers disease, neuropathies, and sleep disorders as well as the effects of strokes.

The Conway Regional Neuroscience Center has seven staff members, all of whom work for Conway Regional. Drs. Freyaldenhoven and Schluterman are not employed by the health system.

A referral from a primary care physician is required to make an appointment with a neurologist. The phone number for the center is the same as the two neurologists offices, 501-932-0352.

The rest is here:
Health system, neurologists partner to form Conway Regional Neuroscience Center - Log Cabin Democrat